Peptide Analogue for Treatment of Diabetes or Obesity
Summary
USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.
What changed
USPTO published a patent application disclosing a peptide analogue of pancreatic polypeptide (PP) for treating diabetes or obesity. The application covers the composition, methods of treatment using the peptide analogue, and use of the analogue in manufacturing a medicament. The inventors are Nigel Irwin and Peter Flatt.
Affected parties in the pharmaceutical and biotechnology sectors should monitor this application for potential blocking of similar therapeutic approaches in the diabetes and obesity treatment space. Parties developing competing PP-based therapeutics may need to evaluate freedom-to-operate implications once the patent grants.
What to do next
- Monitor for patent grant or office action updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions for Use in the Treatment of Diabetes or Obesity
Application US20260097101A1 Kind: A1 Apr 09, 2026
Inventors
Nigel Irwin, Peter Flatt
Abstract
The present invention relates to compositions for use in the treatment of diabetes or obesity. In one embodiment, the present invention relates to a peptide analogue of pancreatic polypeptide (PP) for use in the treatment of diabetes or obesity. Also disclosed are methods of treatment of diabetes or obesity, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating diabetes or obesity.
CPC Classifications
A61K 38/2271 A61P 3/04 A61P 3/10 A61P 5/48
Filing Date
2023-09-06
Application No.
19110570
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.